Achieve Life Sciences Secures $25M Loan Facility To Fund Smoking Cessation Program

Achieve Life Sciences Inc (NASDAQ: ACHV) has entered into a million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.

• The proceeds and funds available under the debt agreement are expected to fund the completion of the cytisinicline smoking cessation clinical development program.

• Related: Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette Cessation.

• As part of the contingent convertible debt agreement, SVB will fund $15 million in the form of convertible indebtedness. Achieve may borrow additional non-convertible term loans of up to $10 million.

• The outstanding convertible debt may be converted into Achieve's common shares at a conversion price equal to $9.34 per share,

• Price Action: ACHV shares are up 3.11% at $7.80 during the market session on the last check Wednesday.

See more from Benzinga

• Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant

• What's Happening With Allarity Therapeutics Stock Today?

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.